SV

Street Verdict

Analyst Scorecard

INDSWFTLAB · NSE

Ind-Swift Laboratories Limited

₹317.05

-3.98% (-₹13.15)

Prev. close

₹330.2

Volume

4,84,691

Delivery %

49.8%

As of

20 Nov 2026

Price history

₹317.05-₹29.82 (-8.60%) · 3M
18 Aug 2026 → 20 Nov 2026
32034036038040018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Navrattan R. Munjal

Headquarters

Manimajra

Employees

1,388

Key stats

Market cap

₹3,274.24 Cr

P/E ratio (TTM)

38.4

Dividend yield

0.00%

EPS (TTM)

₹9.64

Beta (1Y · daily vs NIFTY 50)

0.71

Beta (5Y · monthly vs NIFTY 50)

0.94

Shares float

3.22 Cr

EPS · quarter ended Jun 2026

₹2.84

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹-25%0%25%50%FY21FY22FY23FY24FY25FY26
RevenueEBITDANet income ÷ revenue

Net income is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY22 (no net income reported).

02 · Earnings Per Share (EPS)

-50050100₹FY21FY22FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

Left off as not meaningful (growth from a very small base, beyond ±400%): Fixed assets FY25 (+3313%).

05 · Capital Structure & Asset Utilization

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0×0.5×1×1.5×2×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹856.58 Cr₹1,038.73 Cr₹1,207.31 Cr₹1,709.15 Cr₹561.71 Cr₹641.29 Cr
EBITDA
₹203.62 Cr₹239.10 Cr₹230.28 Cr₹776.43 Cr₹285.20 Cr₹81.06 Cr
₹-4.40 Cr—₹47.60 Cr₹538.75 Cr₹250.48 Cr₹43.12 Cr
Diluted EPS
₹-0.74₹-0.36₹-4.28₹91.18₹35.21₹5.03

Net income has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹-4.40 Cr while the annual report gives ₹-3.15 Cr (28.4% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹-21.19 Cr) and Net income for Mar 2022 (the annual report alone gives ₹-2.15 Cr) are left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,818.00 Cr₹1,801.00 Cr₹1,824.00 Cr₹1,165.00 Cr₹1,438.00 Cr₹1,673.00 Cr
—₹952.99 Cr₹862.10 Cr₹216.80 Cr₹32.98 Cr₹17.91 Cr
Stockholders' equity
₹604.00 Cr₹601.00 Cr₹682.00 Cr₹931.00 Cr₹1,173.00 Cr₹1,384.00 Cr

Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹135.00 Cr₹150.00 Cr₹195.00 Cr₹-163.00 Cr₹-25.00 Cr₹-70.00 Cr
Investing cash flow
₹-10.17 Cr₹4.77 Cr₹-13.37 Cr₹-27.15 Cr₹-113.13 Cr₹-72.68 Cr
₹-124.00 Cr₹-141.00 Cr₹-186.00 Cr₹699.00 Cr₹69.00 Cr₹142.00 Cr
Capital expenditure
₹-10.68 Cr₹-18.41 Cr₹-12.77 Cr₹-73.01 Cr₹-64.41 Cr₹-87.72 Cr
End cash position
——₹17.07 Cr₹477.19 Cr₹425.11 Cr₹429.85 Cr

End cash position has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Dec 24(15Q)Mar 25–Jun 25(3Q)Jul 25Jul 25Aug 25Aug 25–Dec 25(3Q)Feb 26Mar 26Jun 26
Promoter42.00%40.94%38.57%36.77%37.72%39.50%43.06%42.99%42.93%
Public58.00%59.06%61.43%63.23%62.28%60.50%56.94%57.01%57.07%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Ind-Swift Laboratories Limited₹3,037.43 Cr₹370.5535.72.193.1%0.01+11.4%+264.7%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

INDSWFTLAB

Ind-Swift Laboratories Ltd Q2 PAT Rises 3.5 Times to ₹31.03 Crore

Multibagg AI · 12 days ago

INDSWFTLAB

Ind-Swift Laboratories Ltd (BOM:532305) (Q2 2027) Earnings Call Highlights: PAT Surges 3. ...

Yahoo Finance Australia · 16 days ago